Prognostic significance of p53, bcl-2 and EGFR in carcinoma of the endometrium

被引:18
|
作者
Athanassiadou, P
Petrakakou, E
Liossi, A
Nakopoulou, L
Zerva, C
Dimopoulos, A
Athanassiades, P
机构
[1] Univ Athens, Sch Med, Pathol Lab, Alexandra Hosp, GR-11527 Athens, Greece
[2] Univ Athens, Sch Med, Dept Immunol Lab, Alexandra Hosp, GR-11527 Athens, Greece
[3] Univ Athens, Sch Med, Dept Clin Therapeut, Alexandra Hosp, GR-11527 Athens, Greece
关键词
prognosis; endometrial neoplasms; immunocytochemistry; p53; protein; bcl-1 protooncogene proteins; epidermal growth factor receptors;
D O I
10.1159/000331351
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
OBJECTIVE: To evaluate the part played by several parameters in the prognosis of patients with endometrial carcinoma. STUDY DESIGN: Eighty imprint smears from fresh endometrial tumor specimens were studied immunocytochemically for the expression of p53, bcl-2 and epidermal growth factor receptor. Also, the presence of estrogen receptor (EX) and progesterone receptor (PR) in the tumor tissue was measured. The data obtained were related to survival, and associations were sought between the parameters studied. RESULTS: Strong associations were found between advanced stage, high grade, lymph node metastases at diagnosis, nonendometrioid histology and p53 expression with poor survival. Bcl-2 expression was associated with good five-year survival. ER expression was associated marginally with good five-year survival, but PR expression was not. A strong association was found between p53 and advanced disease, stage and lymph node metastases at diagnosis. An association between EGFR positivity and survival was not found. CONCLUSION: p53 Expression of uterine tumors is an independent and strong indicator of poor prognosis. Even patients with stage I and II disease at surgery who have p53-positive tumors must be considered at high risk.
引用
收藏
页码:1039 / 1044
页数:6
相关论文
共 50 条
  • [31] Prognostic significance of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancer
    Laudanski, J
    Niklinska, W
    Burzykowski, T
    Chyczewski, L
    Niklinski, J
    EUROPEAN RESPIRATORY JOURNAL, 2001, 17 (04) : 660 - 666
  • [32] Prognostic significance of gene-suppressor p53 and Bcl-2 in disseminated kidney cancer
    Nizamov, D.
    Gafur-Akhunov, M.
    Tillyashaikhov, M.
    Nishanov, D.
    Kutliev, O.
    EJC SUPPLEMENTS, 2009, 7 (02): : 438 - 438
  • [33] Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer
    Malamou-Mitsi, Vassiliki
    Crikoni, Olga
    Timotheadou, Eleni
    Aravantinos, Gerassimos
    Vrettou, Eleni
    Agnantis, Niki
    Fountzilas, George
    ANTICANCER RESEARCH, 2007, 27 (02) : 1157 - 1165
  • [34] Expression of Bcl-2 and p53 in the normal, hyperplastic and malignant endometrium.
    Rasty, G
    Lu, L
    Masood, S
    LABORATORY INVESTIGATION, 1996, 74 (01) : 558 - 558
  • [35] Expression of p53 and bcl-2 in adenomas and colorectal carcinoma
    Sundblad, AS
    Chumbita, RL
    Zoppi, JA
    MEDICINA-BUENOS AIRES, 1997, 57 (06) : 662 - 666
  • [36] MDM2 and BCL-2: to p53 or not to p53?
    Wang, Eunice S.
    BLOOD, 2023, 141 (11) : 1237 - 1238
  • [37] P53 and bcl-2 assessment in serous ovarian carcinoma
    Palmer, J. E.
    Cassia, L. J. Sant
    Irwin, C. J.
    Morris, A. G.
    Rollason, T. P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (02) : 241 - 248
  • [38] The p53–Bcl-2 connection
    M T Hemann
    S W Lowe
    Cell Death & Differentiation, 2006, 13 : 1256 - 1259
  • [39] Apoptosis in situ, p53, bcl-2 and AgNOR counts as prognostic factors in laryngeal carcinoma
    Pulkkinen, JO
    Klemi, P
    Martikainen, P
    Grénman, R
    ANTICANCER RESEARCH, 1999, 19 (1B) : 703 - 707
  • [40] Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma
    Uchida, T
    Gao, JP
    Wang, CX
    Jiang, SX
    Muramoto, M
    Satoh, T
    Minei, S
    Shimura, S
    Irie, A
    Kameya, T
    Baba, S
    UROLOGY, 2002, 59 (04) : 615 - 620